Photo Gallery

Wellnex for Diabetes Management

Type 2 diabetes is the fifth leading cause of death in most developed countries and there is growing evidence that it has reached epidemic proportions in many developing and newly industrialized countries. The prevalence of diabetes is rapidly rising all over the globe at an alarming rate. WHO estimates that the total number of diabetic patients over half a billion in the world, of which a quarter live in two populous countries in the world, China and India. This number does not include pre-diabetics which include those with impaired glucose tolerance (IGT). Anti-diabetics is forecast to be the second biggest therapy area with sales of $57.9bn in 2022. It is estimated that globally 415 million people are diagnosed with diabetes and the prevalence rate is 8.8%. 12% of global health expenditure dedicated to diabetes treatment and related complications. India, China, the US are countries with a high population of Diabetes. There are 318 million people in the group (IGT) who are likely to reach diabetic conditions. Over the past 30 years, the status of diabetes has changed from being considered as a mild disorder of the elderly to one of the major causes of morbidity and mortality affecting the youth and middle-aged people. Diabetes mellitus is not a single disease. Diabetes has been recognized to cause several pathophysiological conditions, besides consistently high blood glucose levels. Cardiovascular disease is the most common cause of death in people with diabetes. High blood pressure, high cholesterol, high blood glucose, and other risk factors contribute to increasing the risk of cardiovascular complications. Diabetic nephropathy, kidney disease is more common in people with diabetes than in those without diabetes. Diabetic neuropathy is another major complication affecting the nerves throughout the body due to high blood glucose levels. People with diabetes carry a risk of amputation that may be more than 25 times greater than that of people without diabetes 

 

 

 

 

                                                                                                                                                                    

Collagen derived peptides and its role in Diabetes Management

The Glucose-dependent Insulinotropic Polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) are Incretin hormones responsible for modulating insulin synthesis and secretion and for maintaining the blood glucose at normal levels. The Incretin effect refers to the amplification of glucose-induced insulin secretion elicited by these hormones. The Incretin hormones, Glucagon-like peptide-1, and Glucose-dependent Insulin tropic hormone are, intestinal hormones (secreted from the gastrointestinal tract), which are released in the presence of glucose or nutrients in the gut. But these two Incretin hormones have short half-lives of only 1-2 minutes following their secretion due to the degradation action of an enzyme, Dipeptidyl peptidase (DPP IV). Hence it is understood that inhibition of DPP IV will result in an increment of glucose-induced insulin secretion.

The DPP IV inhibition property of Collagen peptide has great relevance as a natural source for the management of Type 2 diabetes through the Incretin effect. Collagen peptides have been shown to have an Incretin effect, which stimulates glucose-induced insulin release by inhibiting Dipeptidyl Peptidase IV (DPP IV). There are several in vitro and studies in animal models and human clinical trials on the hypoglycaemic effect of collagen-derived peptides, by making use of its ability to inhibit DPPIV.
Clinical Research Findings

Two Double-blind, Placebo-Controlled, Randomized, studies done in India established the benefits of Collagen derived peptides as Add on Nutritional therapy in Diabetes patients. Clinical study findings with 5g dosage for 3 months reported following improvements

                            

 

A Healthy Intervention for Diabetes Management
 

 

References